Hangzhou Alltest Biotech Co. Ltd. A (688606) - Total Assets
Based on the latest financial reports, Hangzhou Alltest Biotech Co. Ltd. A (688606) holds total assets worth CN¥4.11 Billion CNY (≈ $601.28 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Hangzhou Alltest Biotech Co. Ltd. A cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Hangzhou Alltest Biotech Co. Ltd. A - Total Assets Trend (2016–2025)
This chart illustrates how Hangzhou Alltest Biotech Co. Ltd. A's total assets have evolved over time, based on quarterly financial data. See Hangzhou Alltest Biotech Co. Ltd. A (688606) shareholders funds for net asset value and shareholders' equity analysis.
Hangzhou Alltest Biotech Co. Ltd. A - Asset Composition Analysis
Current Asset Composition (December 2025)
Hangzhou Alltest Biotech Co. Ltd. A's total assets of CN¥4.11 Billion consist of 66.8% current assets and 33.3% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 25.2% |
| Accounts Receivable | CN¥159.05 Million | 3.8% |
| Inventory | CN¥176.69 Million | 4.2% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥136.82 Million | 3.2% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how Hangzhou Alltest Biotech Co. Ltd. A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 688606 stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hangzhou Alltest Biotech Co. Ltd. A's current assets represent 66.8% of total assets in 2025, a decrease from 92.0% in 2016.
- Cash Position: Cash and equivalents constituted 25.2% of total assets in 2025, up from 13.2% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 0.0% in 2016.
- Asset Diversification: The largest asset category is inventory at 4.2% of total assets.
Hangzhou Alltest Biotech Co. Ltd. A Competitors by Total Assets
Key competitors of Hangzhou Alltest Biotech Co. Ltd. A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
ESSILORLUXOTTICA 1/2/O.N.
F:ESLC
|
Germany | €63.90 Billion |
|
DIO Corporation
KQ:039840
|
Korea | ₩332.33 Billion |
|
Nyxoah
BR:NYXH
|
Belgium | €93.60 Million |
|
Safe Orthopaedics SA
PA:ALSAF
|
France | €7.94 Million |
|
Ansell Ltd
AU:ANN
|
Australia | AU$3.33 Billion |
|
Nanosonics Ltd
AU:NAN
|
Australia | AU$279.25 Million |
|
SDI Ltd
AU:SDI
|
Australia | AU$135.84 Million |
|
Austco Healthcare Ltd
AU:AHC
|
Australia | AU$91.07 Million |
Hangzhou Alltest Biotech Co. Ltd. A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 12.36 | 11.70 | 16.58 |
| Quick Ratio | 11.51 | 11.06 | 15.71 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥2.47 Billion | CN¥2.72 Billion | CN¥2.67 Billion |
Hangzhou Alltest Biotech Co. Ltd. A - Advanced Valuation Insights
This section examines the relationship between Hangzhou Alltest Biotech Co. Ltd. A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.96 |
| Latest Market Cap to Assets Ratio | 0.12 |
| Asset Growth Rate (YoY) | 1.3% |
| Total Assets | CN¥4.24 Billion |
| Market Capitalization | $496.65 Million USD |
Valuation Analysis
Below Book Valuation: The market values Hangzhou Alltest Biotech Co. Ltd. A's assets below their book value (0.12x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Hangzhou Alltest Biotech Co. Ltd. A's assets grew by 1.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Hangzhou Alltest Biotech Co. Ltd. A (2016–2025)
The table below shows the annual total assets of Hangzhou Alltest Biotech Co. Ltd. A from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥4.24 Billion ≈ $620.80 Million |
+1.35% |
| 2024-12-31 | CN¥4.19 Billion ≈ $612.55 Million |
+1.70% |
| 2023-12-31 | CN¥4.12 Billion ≈ $602.31 Million |
-12.42% |
| 2022-12-31 | CN¥4.70 Billion ≈ $687.72 Million |
+17.25% |
| 2021-12-31 | CN¥4.01 Billion ≈ $586.55 Million |
+248.22% |
| 2020-12-31 | CN¥1.15 Billion ≈ $168.44 Million |
+246.19% |
| 2019-12-31 | CN¥332.50 Million ≈ $48.66 Million |
+30.62% |
| 2018-12-31 | CN¥254.56 Million ≈ $37.25 Million |
+33.57% |
| 2017-12-31 | CN¥190.58 Million ≈ $27.89 Million |
+219.06% |
| 2016-12-31 | CN¥59.73 Million ≈ $8.74 Million |
-- |
About Hangzhou Alltest Biotech Co. Ltd. A
Hangzhou Alltest Biotech Co., Ltd. engages in the research, development, production, and sale of in vitro diagnostic reagents in China and internationally. The company offers rapid diagnostic reagents, including drug and drug abuse, infectious disease, women's health, tumor marker, and cardiac marker testing products. Its products include COVID-19 antigen and antibody tests; veterinary tests; flu… Read more